COVID-19 in a patient with sporadic lymphangioleiomyomatosis awaiting lung transplantation.
COVID-19
COVID-19, coronavirus disease 2019
CT, computed tomography
LAM, lymphangioleiomyomatosis
Lung transplantation
Lymphopenia
Sporadic lymphangioleiomyomatosis
mTOR, mammalian target of rapamycin
Journal
Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
04
2021
revised:
13
08
2021
accepted:
01
09
2021
entrez:
8
9
2021
pubmed:
9
9
2021
medline:
9
9
2021
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) is an emerging viral disease with a mortality that depends on the individual's condition. Underlying comorbidities are major risk factors for COVID-19-related morbidity and mortality. However, information regarding the clinical course of COVID-19 in patients with rare respiratory system diseases is lacking. Here, we present a case of severe COVID-19 in a patient with advanced sporadic lymphangioleiomyomatosis (LAM) who was awaiting lung transplantation. She experienced a marked worsening of her respiratory status despite the limited size of the infiltrations seen on chest computed tomography. She responded to treatment with dexamethasone and remdesivir, and did not require mechanical ventilation. She recovered her pre-COVID-19 respiratory function. This case illustrates that patients with severe lung parenchymal destruction due to advanced LAM are at risk of worsening hypoxemia, but may not have a bad outcome if managed appropriately. Prevention and early diagnosis of COVID-19 are crucial in patients with advanced LAM. Future studies are needed to improve understanding of the clinical features and optimal treatment of COVID-19 in patients with LAM.
Identifiants
pubmed: 34493971
doi: 10.1016/j.rmcr.2021.101505
pii: S2213-0071(21)00167-2
pmc: PMC8413486
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101505Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors state that they have no conflicts of interest (COI).
Références
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Chest. 2004 Dec;126(6):1867-74
pubmed: 15596686
N Engl J Med. 2011 Apr 28;364(17):1595-606
pubmed: 21410393
J Med Virol. 2020 Sep;92(9):1495-1500
pubmed: 32410266
N Engl J Med. 1990 Nov 1;323(18):1254-60
pubmed: 2215609
J Surg Case Rep. 2015 Nov 09;2015(11):
pubmed: 26552407
N Engl J Med. 1996 Oct 24;335(17):1275-80
pubmed: 8857007
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Am J Med Genet A. 2020 Nov;182(11):2479-2485
pubmed: 32804431
Chem Biol Interact. 2020 Nov 1;331:109282
pubmed: 33031791
Am J Respir Crit Care Med. 2016 Sep 15;194(6):748-61
pubmed: 27628078
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
Radiology. 2020 Jun;295(3):200463
pubmed: 32077789
Am J Respir Crit Care Med. 2017 Nov 15;196(10):1337-1348
pubmed: 29140122
Eur Respir J. 2021 Feb 11;57(2):
pubmed: 33060154